Aya Takahashi1, Michihisa Moriguchi2, Yuya Seko1, Hiroki Ishikawa3, Takaharu Yo3, Hiroyuki Kimura4, Hideki Fujii4, Toshihide Shima5, Yasuhide Mitsumoto5, Hiroshi Ishiba6, Hidetaka Takashima7, Yasuyuki Nagao8, Masayasu Jo9, Masahiro Arai10, Tasuku Hara11, Akira Okajima12, Akira Muramatsu13, Atsuhiro Morita14, Naomi Yoshinami15, Tomoki Nakajima16, Hironori Mitsuyoshi17, Atsushi Umemura1, Taichiro Nishikawa1, Kanji Yamaguchi1, Yoshito Itoh1. 1. Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan. 2. Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan mmori@koto.kpu-m.ac.jp. 3. Department of Gastroenterology and Hepatology, Omihachiman Community Medical Center, Shiga, Japan. 4. Department of Gastroenterology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan. 5. Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Osaka, Japan. 6. Department of Gastroenterology and Hepatology, North Medical Center of Kyoto Prefectural University of Medicine, Kyoto, Japan. 7. Department of Gastroenterology, Osaka General Hospital of West Japan Railway Company, Osaka, Japan. 8. Department of Gastroenterology, Matsushita Memorial Hospital, Osaka, Japan. 9. Department of Gastroenterology, Otsu City Hospital, Shiga, Japan. 10. Department of Gastroenterology, Kyoto Yamashiro General Medical Center, Kyoto, Japan. 11. Department of Gastroenterology, Fukuchiyama City Hospital, Kyoto, Japan. 12. Department of Gastroenterology, Koseikai Takeda Hospital, Kyoto, Japan. 13. Department of Gastroenterology, Akashi City Hospital, Hyogo, Japan. 14. Department of Gastroenterology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan. 15. Department of Gastroenterology, Kyoto City Hospital, Kyoto, Japan. 16. Department of Gastroenterology, Saiseikai Kyoto Hospital, Kyoto, Japan. 17. Department of Gastroenterology and Hepatology, Kyoto Chubu Medical Center, Kyoto, Japan.
Abstract
BACKGROUND: Factors associated with response to lenvatinib have not been clarified in patients with hepatocellular carcinoma (HCC). PATIENTS AND METHODS: This study retrospectively analyzed 50 patients treated with lenvatinib as first-line therapy between March 2018 and March 2019. Patients were divided into two groups by the Modified Response Evaluation Criteria in Solid Tumours (mRECIST) (responders and non-responders, whose best overall responses were complete (CR)/partial response (PR) and stable (SD)/progressive disease (PD), respectively). Factors associated with response were assessed, including the relative dose intensity 8 weeks after lenvatinib induction (8W-RDI). RESULTS: The best overall responses were 0/22/14/14 of CR/PR/SD/PD. Multivariate analysis revealed that only 8W-RDI was significantly associated with response. The receiver operating characteristic curve for 8W-RDI in differentiating responders from non-responders revealed a cut-off value of 75%. Patients with 8W-RDI ≥75% experienced a higher response rate and longer progression-free survival than patients with 8W-RDI <75%. CONCLUSION: Our results suggest that maintaining an RDI ≥75% during the initial 8 weeks of lenvatinib treatment has a favorable impact on response. Copyright
BACKGROUND: Factors associated with response to lenvatinib have not been clarified in patients with hepatocellular carcinoma (HCC). PATIENTS AND METHODS: This study retrospectively analyzed 50 patients treated with lenvatinib as first-line therapy between March 2018 and March 2019. Patients were divided into two groups by the Modified Response Evaluation Criteria in Solid Tumours (mRECIST) (responders and non-responders, whose best overall responses were complete (CR)/partial response (PR) and stable (SD)/progressive disease (PD), respectively). Factors associated with response were assessed, including the relative dose intensity 8 weeks after lenvatinib induction (8W-RDI). RESULTS: The best overall responses were 0/22/14/14 of CR/PR/SD/PD. Multivariate analysis revealed that only 8W-RDI was significantly associated with response. The receiver operating characteristic curve for 8W-RDI in differentiating responders from non-responders revealed a cut-off value of 75%. Patients with 8W-RDI ≥75% experienced a higher response rate and longer progression-free survival than patients with 8W-RDI <75%. CONCLUSION: Our results suggest that maintaining an RDI ≥75% during the initial 8 weeks of lenvatinib treatment has a favorable impact on response. Copyright
Authors: I G Rapposelli; S Shimose; T Kumada; S Okamura; A Hiraoka; G G Di Costanzo; F Marra; E Tamburini; A Forgione; F G Foschi; M Silletta; S Lonardi; G Masi; M Scartozzi; M Nakano; H Shibata; K Kawata; A Pellino; C Vivaldi; E Lai; A Takata; K Tajiri; H Toyoda; R Tortora; C Campani; M G Viola; F Piscaglia; F Conti; C A M Fulgenzi; G L Frassineti; M D Rizzato; F Salani; G Astara; T Torimura; M Atsukawa; T Tada; V Burgio; M Rimini; S Cascinu; A Casadei-Gardini Journal: ESMO Open Date: 2021-06-15